Logo image of GKOS

GLAUKOS CORP (GKOS) Stock Fundamental Analysis

NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD

125.88  -31.48 (-20.01%)

After market: 126 +0.12 (+0.1%)

Fundamental Rating

3

GKOS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GKOS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GKOS had negative earnings in the past year.
In the past year GKOS has reported a negative cash flow from operations.
In the past 5 years GKOS always reported negative net income.
In the past 5 years GKOS reported 4 times negative operating cash flow.
GKOS Yearly Net Income VS EBIT VS OCF VS FCFGKOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

GKOS's Return On Assets of -16.14% is in line compared to the rest of the industry. GKOS outperforms 55.32% of its industry peers.
With a Return On Equity value of -22.37%, GKOS perfoms like the industry average, outperforming 59.57% of the companies in the same industry.
Industry RankSector Rank
ROA -16.14%
ROE -22.37%
ROIC N/A
ROA(3y)-9.65%
ROA(5y)-7.8%
ROE(3y)-18.78%
ROE(5y)-14.41%
ROIC(3y)N/A
ROIC(5y)N/A
GKOS Yearly ROA, ROE, ROICGKOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10 -20 -30

1.3 Margins

The Gross Margin of GKOS (76.61%) is better than 89.36% of its industry peers.
GKOS's Gross Margin has declined in the last couple of years.
GKOS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.68%
GM growth 5Y-2.48%
GKOS Yearly Profit, Operating, Gross MarginsGKOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for GKOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GKOS Yearly Shares OutstandingGKOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
GKOS Yearly Total Debt VS Total AssetsGKOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 19.50 indicates that GKOS is not in any danger for bankruptcy at the moment.
GKOS has a better Altman-Z score (19.50) than 94.15% of its industry peers.
A Debt/Equity ratio of 0.19 indicates that GKOS is not too dependend on debt financing.
The Debt to Equity ratio of GKOS (0.19) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z 19.5
ROIC/WACCN/A
WACC8.67%
GKOS Yearly LT Debt VS Equity VS FCFGKOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 5.54 indicates that GKOS has no problem at all paying its short term obligations.
The Current ratio of GKOS (5.54) is better than 80.85% of its industry peers.
GKOS has a Quick Ratio of 4.71. This indicates that GKOS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.71, GKOS belongs to the top of the industry, outperforming 80.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.54
Quick Ratio 4.71
GKOS Yearly Current Assets VS Current LiabilitesGKOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.30% over the past year.
EPS 1Y (TTM)16.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%28.09%

3.2 Future

Based on estimates for the next years, GKOS will show a very strong growth in Earnings Per Share. The EPS will grow by 27.39% on average per year.
GKOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.76% yearly.
EPS Next Y43.69%
EPS Next 2Y36.56%
EPS Next 3Y30.51%
EPS Next 5Y27.39%
Revenue Next Year26.68%
Revenue Next 2Y26.91%
Revenue Next 3Y25.32%
Revenue Next 5Y20.76%

3.3 Evolution

GKOS Yearly Revenue VS EstimatesGKOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
GKOS Yearly EPS VS EstimatesGKOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GKOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GKOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GKOS Price Earnings VS Forward Price EarningsGKOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GKOS Per share dataGKOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as GKOS's earnings are expected to grow with 30.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.56%
EPS Next 3Y30.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GKOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLAUKOS CORP

NYSE:GKOS (2/21/2025, 8:23:50 PM)

After market: 126 +0.12 (+0.1%)

125.88

-31.48 (-20.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)04-29 2025-04-29/amc
Inst Owners99.97%
Inst Owner Change4.89%
Ins Owners3.23%
Ins Owner Change0.24%
Market Cap6.94B
Analysts82.86
Price Target163.99 (30.27%)
Short Float %6.29%
Short Ratio5.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.77%
Min EPS beat(2)1.01%
Max EPS beat(2)42.53%
EPS beat(4)2
Avg EPS beat(4)2.92%
Min EPS beat(4)-19.53%
Max EPS beat(4)42.53%
EPS beat(8)5
Avg EPS beat(8)3.66%
EPS beat(12)8
Avg EPS beat(12)0.29%
EPS beat(16)12
Avg EPS beat(16)10.91%
Revenue beat(2)2
Avg Revenue beat(2)4.56%
Min Revenue beat(2)3.59%
Max Revenue beat(2)5.53%
Revenue beat(4)4
Avg Revenue beat(4)4.17%
Min Revenue beat(4)2.12%
Max Revenue beat(4)5.53%
Revenue beat(8)8
Avg Revenue beat(8)4.19%
Revenue beat(12)12
Avg Revenue beat(12)4.74%
Revenue beat(16)15
Avg Revenue beat(16)4.4%
PT rev (1m)3.08%
PT rev (3m)16.45%
EPS NQ rev (1m)1.3%
EPS NQ rev (3m)5.64%
EPS NY rev (1m)0%
EPS NY rev (3m)2.4%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.26
P/FCF N/A
P/OCF N/A
P/B 10.38
P/tB 20.85
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.31
OCFYN/A
SpS6.54
BVpS12.12
TBVpS6.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.14%
ROE -22.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.61%
FCFM N/A
ROA(3y)-9.65%
ROA(5y)-7.8%
ROE(3y)-18.78%
ROE(5y)-14.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.68%
GM growth 5Y-2.48%
F-Score4
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.8%
Cap/Sales 2.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.54
Quick Ratio 4.71
Altman-Z 19.5
F-Score4
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)105.72%
Cap/Depr(5y)83.12%
Cap/Sales(3y)11.13%
Cap/Sales(5y)7.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.51%
EPS Next Y43.69%
EPS Next 2Y36.56%
EPS Next 3Y30.51%
EPS Next 5Y27.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%28.09%
Revenue Next Year26.68%
Revenue Next 2Y26.91%
Revenue Next 3Y25.32%
Revenue Next 5Y20.76%
EBIT growth 1Y6.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.92%
EBIT Next 3Y30.05%
EBIT Next 5Y34.04%
FCF growth 1Y-25.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-115.75%
OCF growth 3YN/A
OCF growth 5YN/A